News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Rebecca Shatsky: One of our MOST innovative I-SPY 2 trial arms ever got accepted at ASCO2024 as an oral presentation
Photo from Rebecca Shatsky/X
Apr 13, 2024, 12:50

Rebecca Shatsky: One of our MOST innovative I-SPY 2 trial arms ever got accepted at ASCO2024 as an oral presentation

Rebecca Shatsky shared a post on X:

“Very happy to announce that 1 of our MOST innovative I-SPY 2 trial arms ever got accepted at ASCO2024 as an oral presentation. I also happen to be f1st author on this 1 . If you want to talk PERSONALIZED curative intent breast cancer therapy come hear me speak on June 3rd!

Hope to make my beloved I-SPY 2 trial team proud and spread the word about the incredible work that is being done to love the field of breast cancer therapy forward. For newly diagnosed patients, this is a trial you should learn about. There is nothing like it out there!
And for other institutions with high volume of breast cancer patients! Please consider joining the I-SPY collaborative. We are open at 30+ institutions around the country and would love to work with you!!!!”

Source: Rebecca Shatsky/X

Rebecca A. Shatsky is an Associate Professor of Medicine and a board-certified medical oncologist at the University of California, San Diego. She specializes in treating breast cancer and is part of UC San Diego Health’s Precision Immunotherapy Clinic. Dr. Shatsky is a member of the NCCN guideline panel for Genetic/High-Risk Assessment of Breast, Ovarian, and Pancreatic Cancer and the panel for the treatment of Cancer-Associated Pain. Dr. Shatsky is a well known social media influencer.

ASCO2024 breast cancer therapy cancer I-SPY 2 trial OncoDaily Oncology Rebecca Shatsky
Special Coverage
Career
Dec 21, 2024, 07:45
OncoInfluencers to Follow on Social Media: Dr. Liang Cheng
Insight
Dec 21, 2024, 07:31
Update on U.S. regulatory review of subcutaneous amivantamab for EGFR + lung cancer
Science
Dec 21, 2024, 07:05
Naseema Gangat: Practical prognostic tool for the current standard of care in older/unfit AML
Blog
Dec 21, 2024, 05:54
LCC in Spanish: LALCA 2024 Highlights
Blog
Dec 21, 2024, 05:50
The Opportunities Are Endless: CU Cancer Center leader Enrique Soto Pérez de Celis signs key international agreement
Insight
Dec 21, 2024, 05:42
Raffaella Casolino: How to integrate cancer into crisis?
Insight
Dec 21, 2024, 05:01
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Blog
Dec 21, 2024, 05:01
Omolola Salako: A year ago, Pearl Oncology Specialist Hospital became a 24-hour, 10-bed cancer center
Science
Dec 21, 2024, 04:57
Alexandre Chan: Updates on repurposing riluzole as a treatment for cancer-related cognitive impairment
Blog
Dec 21, 2024, 04:55
Milan Mishkovikj: The Patient at the Center - Value-Based Healthcare in Oncology
Insight
Dec 21, 2024, 04:52
Do national cancer control plans address care and research for children and AYAs - SIOP
Insight
Dec 21, 2024, 04:36
A holistic global strategy for incorporating cancer care into crisis response initiatives - The Institute of Cancer and Crisis